Skip to content

Kymera Therapeutics

Request correction

A clinical-stage biotechnology company developing medicines based on targeted protein degradation.

Last updated September 11, 2026

AI crawler reads

2requests

1companies
  • Anthropic2
Profile
2
Controversies
0
JSON · MD
0
First read
Nov 4, 2026
Latest read
Nov 4, 2026

From this site's server log

Overview

Kymera Therapeutics describes itself as a clinical-stage biotechnology company working to reinvent the treatment of human disease through innovative, highly differentiated medicines. It is committed to advancing novel technologies such as targeted protein degradation to address previously undrugged disease-causing proteins, and states that it has built a discovery engine capable of advancing at least one new program into clinical testing every year. Its leadership team includes Founder, President & CEO Nello Mainolfi, PhD.

History

Kymera Therapeutics is a clinical-stage biotechnology company that states it is working to reinvent the treatment of human disease through innovative, highly differentiated medicines. It is committed to advancing novel technologies such as targeted protein degradation to address previously undrugged disease-causing proteins. The company states that since its founding it has built a discovery engine capable of identifying new drug candidates at an accelerated pace and advancing at least one new program into clinical testing every year. Its leadership includes Founder, President & CEO Nello Mainolfi, PhD, and Co-Founder Bruce Booth, DPhil, who serves as a board member.

Products and positioning

Clinical-stage biotechnology company focused on targeted protein degradation and first-in-class therapeutics.

Recent events

  • Reported

    A-Alpha Bio and Kymera Therapeutics announce discovery partnership[5]

    A-Alpha Bio and Kymera Therapeutics announced a partnership to discover and characterize novel pairs of E3 ubiquitin ligases and high-value therapeutic targets for the design and development of molecular glues.

  • Reported

    Kymera appoints Juliet Williams as senior vice president, head of biology[6]

    Kymera Therapeutics announced the appointment of Juliet Williams, PhD, as Senior Vice President, Head of Biology.

Read more

Sources6 sources

Cite this profile: Cite the canonical profile. /brand-wiki/kymera-therapeutics · Editorial policy · How profiles are compiled